ImmunoGen Doubles on ELAHERE Phase 3 MIRASOL Trial Announcement
(24/7 MARKET NEWS) – ImmunoGen Inc. (NASDAQ:IMGM) announced, this morning, positive top-line data from the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer who have received one to three prior lines of therapy.
ImmunoGen is trading at $10.38, up $5.18 (+99.62%), on 10.64M premarket shares traded.
Its 52-week range is $3.095 to $6.63. This is trading at multiyear highs and, if the trading volume remains strong, it could try to challenge its 2018 trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.